A study of 514 patients between 60-70 years old with de novo myelodysplastic syndromes (MDS) has shown that for patients with intermediate-2/high International Prognostic Scoring System (IPSS) scores, a reduced-intensity allogeneic transplant leads to a significantly longer life expectancy (LE) compared to non-transplantation therapies: 36 months vs. 28 months, respectively (p<0.001). Non-transplant treatments were best supportive care, hematopoietic growth factors, and hypomethylating agents. For patients with low/intermediate-1 IPSS scores, non-transplantation approaches led to significantly longer LE compared to reduced-intensity transplant: 77 months vs. 38 months, respectively (p<0.001).
Comparing Transplant vs. Non-Transplant for De Novo MDS by IPSS Score
Jul 2013